Unending saga of fighting cholesterol: Evacetrapib is another fallen warrior

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Statins and antihypertensives have reduced cardiovascular disease (CVD) morbidity and mortality but are not universally effective.
• Research into dyslipidemia targets has yielded mixed results, with significant investment in CETP inhibitors.
• The failure of evacetrapib highlights the need for novel therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy of CETP inhibition in cardiovascular disease patients.
• To explore alternative molecular targets for normalizing dyslipidemia.
• To identify treatments that improve lipid profiles without adverse effects on essential lipids.

Main Methods:

• Clinical trial of evacetrapib, a CETP inhibitor, in CVD patients.
• Analysis of lipid profiles, including high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).
• Comparison of cardiovascular event rates between the evacetrapib group and placebo.

Main Results:

• Evacetrapib significantly increased HDL-C and decreased LDL-C.
• Despite significant lipid changes, evacetrapib showed no improvement in CVD outcomes compared to placebo.
• The trial demonstrated the limitations of targeting CETP for cardiovascular benefit.

Conclusions:

• Targeting CETP with evacetrapib is ineffective for reducing cardiovascular events in patients.
• The failure of evacetrapib suggests that altering HDL-C and LDL-C levels through CETP inhibition is not sufficient for CVD risk reduction.
• PCSK9 inhibitors represent a promising alternative for managing dyslipidemia and potentially improving cardiovascular outcomes.